We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The EMA Management Board has advanced the development of a web portal that will provide free information on European medicines across the products’ lifecycle. Read More
The UK’s price watchdog is backing Celgene’s Otezla as a standalone or combined treatment for active psoriatic arthritis when other options are ineffective or not tolerated, provided the company discounts its price. Read More
Bristol-Myers Squibb presented results from several clinical trials of its PD-L1 immunotherapy, Opdivo, including more detailed data from a Phase III trial that failed to show benefits as a first-line monotherapy in advanced non-small cell lung cancer. Read More
The pharmaceutical industry is generally satisfied with the EMA’s redesigned post-approval procedures, but would like some clarity on how to tackle more complex filings, according to an EMA survey. Read More
The Yangzhou Hengyuan Daily Chemical Plastic Co. received a warning letter after the FDA found that one of its drugs was missing the active ingredient and that the company was not testing finished batches of drug products. Read More